Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodevelopmental Disorder Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SYNGAP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SYNGAP1 Recombinant Protein (GAP Domain / Full-Length) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View SYNGAP1 Products |
| Gene Delivery | SYNGAP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and expression rescue assays. |
View SYNGAP1 Products |
| Benchmark Ab | Anti-SYNGAP1 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and ELISA validation. |
View SYNGAP1 Products |
| Validator | SYNGAP1 siRNA Set For target knockdown verification and specificity controls. |
View SYNGAP1 Products |
| Related Target A | GRIN2B Encodes the GluN2B subunit of NMDA receptors; physically interacts with SYNGAP1 at the postsynaptic density. |
View GRIN2B Products |
| Related Target B | DLG4 PSD-95 scaffolding protein that anchors SYNGAP1 and NMDA receptors to regulate synaptic plasticity. |
View DLG4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-Domain Structure (150+ kDa) | Domain-specific truncated proteins (e.g., GAP domain) and full-length proteins with verified molecular weight and high purity (>95%). |
| Haploinsufficiency Rescue Validation | High-titer Lentivirus premade particles for stable over-expression to validate therapeutic rescue (ASO/small molecule read-through). |
| Lack of Controls | Sequence-verified clinical benchmark recombinant antibodies included. |
| False Positives in Screening | Sequence-specific validated siRNA pool included for target knockdown and assay specificity checks. |
Live SYNGAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SYNGAP1 therapeutics is intensifying, with major players shifting focus from traditional small molecules to genetic medicines. As first-generation therapies reach preclinical and early clinical milestones, the next wave of R&D is targeting haploinsufficiency rescue using antisense oligonucleotides (ASOs), gene replacement therapies, and mRNA-based therapeutics. Because SYNGAP1 is a major scaffolding protein at the postsynaptic density, preserving native conformation and domain-specific interactions is critical for developing effective modifiers of synaptic plasticity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antisense Oligonucleotides (ASO) | Stoke Therapeutics, Praxis Precision Medicines | SYNGAP1-Related Encephalopathy, Epilepsy | Target upregulation validation (Need Lentivirus/qPCR assays) |
| Gene Therapy (AAV) | Latus Bio, Prevail Therapeutics / Eli Lilly | Neurodevelopmental Disorders, Intellectual Disability | Transgene expression & functional rescue (Need high-purity protein for ELISA/Western Blot verification) |
| Small Molecule (Read-through) | Ultragenyx, Academic Collaborations | Nonsense Mutation-mediated SYNGAP1 deficiency | Functional rescue assays (Need mutant vs WT recombinant proteins) |